American Journal of Respiratory and Critical Care Medicine · 2006 · 462 citations · 31 references
MedicineClinical SciencesInflammationPulmonary Function TestingPulmonologyChronic Obstructive Pulmonary DiseaseInflammatory BiomarkersObstructive Lung DiseasePulmonary InflammationBiomarkersC-reactive Protein TestingChronic Obstructive Pulmonary Disease AssessmentDiagnostic Inflammatory BiomarkersExacerbation Severity AssessmentPlasma Protein BiomarkersSymptom-based DiagnosisSystemic Inflammation Markers
IMPACT: This study explores the use of measuring plasma biomarkers at exacerbation of chronic obstructive pulmonary disease (COPD), providing insight into the underlying pathogenesis of these important events. RATIONALE: The use of measuring C-reactive protein (CRP) to confirm exacerbation, or to assess exacerbation severity, in COPD is unclear. Furthermore, it is not known whether there may be more useful systemic biomarkers. OBJECTIVE: To assess the use of plasma biomarkers in confirming exacerbation and predicting exacerbation severity. METHODS: We assessed 36 biomarkers in 90 paired baseline and exacerbation plasma samples from 90 patients with COPD. The diagnosis of exacerbation fulfilled both health care use and symptom-based criteria. Biomarker concentrations were related to clinical indices of exacerbation severity. Interrelationships between biomarkers were examined to gain information on mechanisms of systemic inflammation at exacerbation of COPD. MEASUREMENTS AND MAIN RESULTS: To confirm the diagnosis of exacerbation, the most selective biomarker was CRP. However, this was neither sufficiently sensitive nor specific alone (area under the receiver operating characteristic curve [AUC], 0.73; 95% confidence interval, 0.66-0.80). The combination of CRP with any one increased major exacerbation symptom recorded by the patient on that day (dyspnea, sputum volume, or sputum purulence) significantly increased the AUC to 0.88 (95% confidence interval, 0.82-0.93; p<0.0001). There were no significant relationships between biomarker concentrations and clinical indices of exacerbation severity. Interrelationships between biomarkers suggest that the acute-phase response is related, separately, to monocytic and lymphocytic-neutrophilic pathways. CONCLUSIONS: Plasma CRP concentration, in the presence of a major exacerbation symptom, is useful in the confirmation of COPD exacerbation. Systemic biomarkers were not helpful in predicting exacerbation severity. The acute-phase response at exacerbation was most strongly related to indices of monocyte function.
31
Basic principles of ROC analysis
Charles E. Metz · Seminars in Nuclear Medicine · 1978 · 6.1K citations
C-reactive protein: a critical update
Mark B. Pepys, Gideon M. Hirschfield · Journal of Clinical Investigation · 2003 · 3.4K citations · Full text